Conv. Plasma
Nigella Sativa
Peg.. Lambda

All antiandrogen studies
Meta analysis
Home COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery time 77% Improvement Relative Risk Recovery time (b) 83% Time to viral- 38% Spironolactone  Cadegiani et al.  EARLY TREATMENT Is early treatment with antiandrogens beneficial for COVID-19? Prospective study of 270 patients in Brazil Faster recovery (p=0.0062) and viral clearance (p=0.015) Cadegiani et al., medRxiv, October 2020 Favors spironolactone Favors control

An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870
Oct 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared to both other HA patients and non-HA patients. SOC included other treatments and there was no mortality or hospitalization. This study is excluded in the after exclusion results of meta analysis: significant unadjusted differences between groups.
recovery time, 76.7% lower, relative time 0.23, p = 0.006, treatment 8, control 262, excluding anosmia.
recovery time, 82.8% lower, relative time 0.17, p = 0.002, treatment 8, control 262, including anosmia.
time to viral-, 37.9% lower, relative time 0.62, p = 0.02, treatment 8, control 262.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cadegiani et al., 6 Oct 2020, prospective, Brazil, preprint, 4 authors, average treatment delay 3.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
MD, MSc Flavio A Cadegiani, Andy Goren, Carlos G Wambier, John Mccoy
Background: While COVID-19 remains largely unclear and mortality continues to raise, early effective approaches prior to complications lack, as well as researches for characterization and therapeutical potential options in actual early COVID-19. Although females seem to be less affected than females, hyperandrogenic (HA) phenotype, like polycystic ovary syndrome (PCOS), idiopathic hirsutism, congenital adrenal hyperplasia (CAH) female androgenetic alopecia (AGA), or idiopathic HA may be at higher risk due to its inherent enhanced androgenic activity. The present study aimed to evaluate the effects of any early pharmacological approach to females diagnosed with COVID-19 .
Cadegiani, Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?, Am J Physiol Endocrinol Metab, doi:10.1152/ajpendo.00136.2020
Cadegiani, Goren, Wambier, Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS), Med Hypotheses, doi:10.1016/j.mehy.2020.110112
Cadegiani, Repurposing existing drugs for COVID-19: an endocrinology perspective, BMC Endocr Disord, doi:10.1186/s12902-020-00626-0
Cadegiani, Wambier, Goren, Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2019014
Clauw, Häuser, Cohen, Fitzcharles, Considering the potential for an increase in chronic pain after the COVID-19 pandemic, Pain, doi:10.1097/j.pain.0000000000001950
Goren, Mccoy, Wambier, What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy
Goren, Vano-Galvan, Wambier, A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain -A potential clue to the role of androgens in COVID-19 severity
Goren, Wambier, Herrera, Mccoy, Vaño-Galván et al., Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16953
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hajifathalian, Kumar, Newberry, Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City, Obesity, doi:10.1002/oby.22923
Kalligeros, Shehadeh, Mylona, Association of Obesity with Disease Severity among Patients with COVID-19, Obesity, doi:10.1002/oby.22859
Kim, Kim, Ra, Lee, Bae et al., Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.04.040
Kragholm, Andersen, Gerds, Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) -a Danish nationwide, register-based study, Clin Infect Dis
Lauer, Grantz, Bi, The Incubation Period of Coronavirus Disease
Lechien, Chiesa-Estomba, Siati, Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study, Eur Arch Otorhinolaryngol, doi:10.1007/s00405-020-05965-1
Mccoy, Wambier, Herrera, Vaño-Galván, Gioia et al., Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients, J Eur Acad Dermatol Venereol
Novak, Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report, eNeurologicalSci, doi:10.1016/j.ensci.2020.100276
Palaiodimos, Kokkinidis, Li, Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, Metabolism
Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med, doi:10.1111/joim.13091
Stokes, Zambrano, Anderson, Coronavirus Disease 2019 Case Surveillance -United States, January 22, MMWR Morb Mortal Wkly Rep
Tong, Wong, Zhu, Fastenberg, Tham, The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Metaanalysis, Otolaryngol Head Neck Surg, doi:10.1177/0194599820926473
Wu, Chen, Cai, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan
Wu, Chen, Cai, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop